Surya Pharmaceutical Ltd.
| BSE: 532516 | Sector: Health care |
| NSE: SURYAPHARM | ISIN Code: INE249G01020 |
| BSE 00:00 | 24 Feb | Surya Pharmaceutical Ltd |
| NSE 05:30 | 01 Jan | Surya Pharmaceutical Ltd |
| OPEN | 0.22 |
| PREVIOUS CLOSE | 0.22 |
| VOLUME | 241733 |
| 52-Week high | 0.23 |
| 52-Week low | 0.00 |
| P/E | 0.02 |
| Mkt Cap.(Rs cr) | 4 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.23 |
| Sell Qty | 1.00 |
Surya Pharmaceutical Ltd. (SURYAPHARM) - Net Sales
Market Cap
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Sales (Rs crore) |
| Aurobindo Pharma | 726.65 | -1.95 | -0.27 | 15823.68 |
| Cipla | 911.50 | -2.20 | -0.24 | 13900.58 |
| Dr Reddy's Labs | 4959.70 | 28.40 | 0.58 | 13349.10 |
| Sun Pharma.Inds. | 841.05 | -1.45 | -0.17 | 12803.21 |
| Lupin | 946.10 | -17.40 | -1.81 | 11055.93 |
| Apollo Hospitals | 4328.80 | -50.00 | -1.14 | 9153.00 |
| Cadila Health. | 544.20 | -1.45 | -0.27 | 7790.40 |
| Glenmark Pharma. | 524.75 | -5.00 | -0.94 | 7567.93 |
| Alkem Lab | 3893.40 | -47.50 | -1.21 | 7219.68 |
| Divi's Lab. | 5373.80 | 127.65 | 2.43 | 6798.61 |
| Torrent Pharma. | 3130.70 | 2.05 | 0.07 | 6450.83 |
| Ipca Labs. | 2421.70 | 60.75 | 2.57 | 5114.11 |
| Alembic Pharma | 806.20 | -10.75 | -1.32 | 5051.44 |
| Laurus Labs | 650.95 | 16.35 | 2.58 | 4768.72 |
| Abbott India | 21544.00 | -26.65 | -0.12 | 4310.02 |
| Gland Pharma | 3779.45 | 2.30 | 0.06 | 3462.88 |
| Glaxosmi. Pharma | 1481.65 | 4.50 | 0.30 | 3193.74 |
| Granules India | 328.45 | -2.35 | -0.71 | 3134.98 |
| Sanofi India | 8154.60 | 60.70 | 0.75 | 2901.90 |
| Ajanta Pharma | 2213.20 | -45.20 | -2.00 | 2718.59 |
Quick Links for Surya Pharmaceutical:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
